gatifloxacin has been researched along with Gram-Negative Bacterial Infections in 12 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Gram-Negative Bacterial Infections: Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimizu, K | 1 |
| Kikuchi, K | 1 |
| Sasaki, T | 1 |
| Takahashi, N | 1 |
| Ohtsuka, M | 1 |
| Ono, Y | 1 |
| Hiramatsu, K | 1 |
| Yamamoto, S | 1 |
| Akiyama, K | 1 |
| Yoshimoto, T | 1 |
| Kanokogi, M | 1 |
| Yabumoto, H | 1 |
| Ihara, H | 1 |
| Ishikawa, E | 1 |
| Yoshioka, M | 1 |
| Kokura, K | 1 |
| Shima, H | 1 |
| Park, JH | 1 |
| Song, NH | 1 |
| Koh, JW | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Ko, WC | 1 |
| Chiang, SR | 1 |
| Lee, HC | 1 |
| Tang, HJ | 1 |
| Wang, YY | 1 |
| Chuang, YC | 1 |
| Dubreuil, L | 1 |
| Behra-Miellet, J | 1 |
| Neut, C | 1 |
| Calvet, L | 1 |
| Hoepelman, I | 1 |
| Ashwath, ML | 1 |
| Katner, HP | 1 |
| Hassoun, A | 1 |
| Eiland, E | 1 |
| Mahapatra, A | 1 |
| Roy, D | 1 |
| Poddar, N | 1 |
| Panda, R | 1 |
| Sarangi, G | 1 |
| Mallick, B | 1 |
| Chayani, N | 1 |
| Blondeau, JM | 1 |
| Laskowski, R | 1 |
| Bjarnason, J | 1 |
| Stewart, C | 1 |
| Cohn, ML | 1 |
| Waites, KB | 1 |
1 review available for gatifloxacin and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gr | 2004 |
11 other studies available for gatifloxacin and Gram-Negative Bacterial Infections
| Article | Year |
|---|---|
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Prim | 2008 |
Clinical efficacy of oral administration of 200 mg gatifloxacin once daily for 3 days for the treatment of patients with uncomplicated cystitis.
Topics: Adult; Anti-Infective Agents; Cystitis; Drug Administration Schedule; Female; Fluoroquinolones; Gati | 2009 |
Achromobacter xylosoxidans keratitis after contact lens usage.
Topics: Achromobacter denitrificans; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Contact Lenses, Ex | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxi | 2003 |
In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; | 2003 |
Pancreatic abscess secondary to Alcaligenes faecalis.
Topics: Abscess; Adult; Alcaligenes faecalis; Anti-Bacterial Agents; Combined Modality Therapy; Drainage; Fl | 2005 |
Effectiveness of flouroquinolone therapy for gram-negative infections within the intensive care unit setting.
Topics: Acinetobacter; Alabama; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia | 2006 |
Chromobacterium violaceum: a case report of an unusual bacterium causing puerperal sepsis.
Topics: Academic Medical Centers; Adult; Amikacin; Anti-Bacterial Agents; Chromobacterium; Female; Fluoroqui | 2006 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gr | 2000 |
Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.
Topics: Anti-Infective Agents; Cross Infection; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infe | 2001 |